Insider Selling: Tilray Brands (NASDAQ:TLRY) Director Sells 33,556 Shares of Stock

Key Points

• Director David Hopkinson sold 33,556 shares on April 21 at an average price of $6.94, a transaction of about $232,879 disclosed on an SEC Form 4.
• Shares rallied roughly 14.2% to $7.87 on very heavy volume (28.7M vs. avg 3.9M), amplified by unusual call-option buying and an exchange LULD pause amid political optimism around U.S. cannabis rescheduling and bullish analyst notes.
• Fundamentally, Tilray missed Q1 EPS (‑$0.24 vs. est. ‑$0.14) and posts wide negative margins with analysts still forecasting negative EPS for the year; the consensus rating is "Hold" with an average price target of $11.50.

Tilray Brands, Inc. (NASDAQ:TLRY - Get Free Report) Director David Hopkinson sold 33,556 shares of the stock in a transaction on Tuesday, April 21st. The stock was sold at an average price of $6.94, for a total transaction of $232,878.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Tilray Brands Trading Up 14.2%

Shares of TLRY stock traded up $0.98 on Wednesday, hitting $7.87. The stock had a trading volume of 28,693,623 shares, compared to its average volume of 3,936,211. The company has a current ratio of 2.79, a quick ratio of 1.66 and a debt-to-equity ratio of 0.19. Tilray Brands, Inc. has a twelve month low of $3.51 and a twelve month high of $23.20. The company has a fifty day moving average price of $7.03 and a two-hundred day moving average price of $9.54. The firm has a market cap of $917.25 million, a P/E ratio of -0.58 and a beta of 2.00.

Tilray Brands (NASDAQ:TLRY - Get Free Report) last announced its earnings results on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.10). The company had revenue of $206.73 million for the quarter, compared to analyst estimates of $201.35 million. Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.During the same quarter last year, the business posted ($0.87) earnings per share. As a group, analysts forecast that Tilray Brands, Inc. will post -0.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

TLRY has been the subject of a number of recent research reports. Wall Street Zen raised Tilray Brands from a "sell" rating to a "hold" rating in a research report on Saturday, March 21st. Canaccord Genuity Group assumed coverage on shares of Tilray Brands in a research report on Tuesday, January 27th. They issued a "hold" rating on the stock. TD Cowen reduced their target price on shares of Tilray Brands from $10.00 to $7.00 and set a "buy" rating for the company in a report on Monday, March 30th. Roth Mkm raised shares of Tilray Brands from a "neutral" rating to a "buy" rating and set a $10.00 target price for the company in a research report on Thursday, April 2nd. Finally, ATB Cormark Capital Markets lowered their price target on shares of Tilray Brands from $9.50 to $9.00 and set a "sector perform" rating on the stock in a research note on Thursday, April 2nd. Three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Tilray Brands presently has a consensus rating of "Hold" and an average price target of $11.50.

Key Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Analysts/technicals point to a recovery — Technical coverage says Tilray is showing an early reversal and breakout as U.S. cannabis rescheduling momentum builds, reinforcing a continuation of the rally. Tilray Brands (TLRY) Price Forecast: Cannabis Rescheduling Fuels Recovery
• Positive Sentiment: Political headlines fueling optimism — Coverage notes a renewed rally after President Trump urged the DOJ to quickly reclassify cannabis to Schedule III, boosting hopes for faster industry tailwinds and option-market bullish positioning. Tilray Stock Pops on New Trump-Driven Cannabis Hopes. Should You Chase the Rally?
• Positive Sentiment: Wall Street bullish note — Roth Capital’s Bill Kirk published a bullish outlook saying TLRY could rise >40% over 12 months based on three positive business developments, which can attract more buy-side interest. 1 Wall Street Analyst Says Tilray Stock Could Jump Over 40%. Should You Believe It?
• Positive Sentiment: Unusually heavy call buying — Traders bought ~45,077 call options today (about +89% vs normal daily call volume), signaling speculative bullish positioning that likely amplified the rally and implied volatility.
• Neutral Sentiment: Trading halt (LULD pause) — The stock experienced an exchange-imposed LULD pause around 11:49 AM due to rapid price movement; this is a volatility-control measure rather than a company-specific announcement.
• Negative Sentiment: Fundamental headwinds remain — Recent Q1 results showed an EPS miss and wide negative margins; analysts still model negative EPS for the year, so while headlines can drive short-term gains, underlying profitability issues could limit sustained upside.

Institutional Trading of Tilray Brands

A number of hedge funds have recently modified their holdings of the stock. Pictet Asset Management Holding SA grew its stake in Tilray Brands by 38.9% in the 1st quarter. Pictet Asset Management Holding SA now owns 18,387 shares of the company's stock valued at $119,000 after buying an additional 5,145 shares during the last quarter. Alpine Global Management LLC bought a new stake in shares of Tilray Brands during the fourth quarter worth approximately $169,000. Voloridge Investment Management LLC bought a new stake in shares of Tilray Brands during the fourth quarter worth approximately $824,000. Polymer Capital Management US LLC acquired a new position in shares of Tilray Brands in the fourth quarter valued at approximately $1,058,000. Finally, Engineers Gate Manager LP bought a new position in shares of Tilray Brands during the fourth quarter worth approximately $126,000. Institutional investors and hedge funds own 9.35% of the company's stock.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray's product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.